Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Marth

Showing results (191-200 of 237) with videos related to

Pageof 24
Sort By:
The Lancet. Oncology|May 12, 2019
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trialIgnace Vergote, Giovanni Scambia, David M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 20, 2021
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, et al.
Plos One|December 14, 2011
Genome-scale screen for DNA methylation-based detection markers for ovarian cancerMihaela Campan, Melissa Moffitt, Sahar Houshdaran, et al.
Gynecologic Oncology|May 19, 2026
A review of reviews of the prevalence of molecular biomarkers in vulvar cancer and their implications for prognosis refinement and treatment strategiesRita Trozzi, Gloria Anderson, Viviana Romano, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 21, 2016
European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer SurgeryDenis Querleu, François Planchamp, Luis Chiva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 25, 2013
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup studyIgnace B Vergote, Antonio Jimeno, Florence Joly, et al.
Cancer|June 17, 2022
Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)Christian Marth, Miguel Henriques Abreu, Klaus Kaae Andersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2024
Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective StudyChristine Brunner, Marjan Arvandi, Christian Marth, et al.
The New England Journal of Medicine|August 27, 2005
A pooled analysis of bone marrow micrometastasis in breast cancerStephan Braun, Florian D Vogl, Bjørn Naume, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 6, 2011
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancerJonathan A Ledermann, Christian Marth, Mark S Carey, et al.
Pageof 24

Showing results (191-200 of 237) with videos related to

Sort By:
Pageof 24
The Lancet. Oncology|May 12, 2019
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trialIgnace Vergote, Giovanni Scambia, David M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 20, 2021
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, et al.
Plos One|December 14, 2011
Genome-scale screen for DNA methylation-based detection markers for ovarian cancerMihaela Campan, Melissa Moffitt, Sahar Houshdaran, et al.
Gynecologic Oncology|May 19, 2026
A review of reviews of the prevalence of molecular biomarkers in vulvar cancer and their implications for prognosis refinement and treatment strategiesRita Trozzi, Gloria Anderson, Viviana Romano, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 21, 2016
European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer SurgeryDenis Querleu, François Planchamp, Luis Chiva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 25, 2013
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup studyIgnace B Vergote, Antonio Jimeno, Florence Joly, et al.
Cancer|June 17, 2022
Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)Christian Marth, Miguel Henriques Abreu, Klaus Kaae Andersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2024
Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective StudyChristine Brunner, Marjan Arvandi, Christian Marth, et al.
The New England Journal of Medicine|August 27, 2005
A pooled analysis of bone marrow micrometastasis in breast cancerStephan Braun, Florian D Vogl, Bjørn Naume, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 6, 2011
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancerJonathan A Ledermann, Christian Marth, Mark S Carey, et al.
Pageof 24